PRICE DIFFERENCES FOR ORPHAN DRUGS ACROSS THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5
Cancer drugs in Germany: HTA decisions of new and innovative oncology drugs in Germany – an analysis using the Prismaccess® database
COMPARISON OF EU5 MARKET ACCESS DECISIONS FOR CROHN’S DISEASE BASED ON THE PRISMACCESS® DATABASe
THE BUDGET IMPACT OF NICOTINIC SUBSTITUTE REIMBURSEMENT
At the end of 2017, the French ministry of health decided to allow the reimbursement of nicotinic substitutes in order to reduce tobacco smoking. Before this decision, patients could only benefit from a fixed e150 per-year reimbursement basis to cover nicotinic substitute expenses (patches and gum).